ArticleJournal of clinical pathology2006
Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.
Article in Journal of clinical pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor.Cancers · 2024Review
- TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma.Journal of Cancer · 2020Article
- Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.Prostate cancer and prostatic diseases · 2016Article
- Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers.The oncologist · 2015Article
- Heterochromatin protein 1 expression is reduced in human thyroid malignancy.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.Endocrine-related cancer · 2013Article
- Race disparities in Wilms tumor incidence and biology.The Journal of surgical research · 2011Article
- Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.Cancer research · 2011Article
- Candidate genes and potential targets for therapeutics in Wilms' tumour.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010Review
- Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.Journal of cellular and molecular medicine · 2009Article
- Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy.The Journal of urology · 2009Article
- Estrogen-dependent and -independent estrogen receptor-alpha signaling separately regulate male fertility.Endocrinology · 2009Article
- The E2F3-Oncomir-1 axis is activated in Wilms' tumor.Cancer research · 2008Article
- CITED1 expression in Wilms' tumor and embryonic kidney.Neoplasia (New York, N.Y.) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTopoisomerase IIalpha (topoIIalpha) is an essential enzyme gene in regulating DNA structure and cell proliferation and is encoded by the TOP2A. Using cDNA microarray analysis, TOP2A has been reported to be one of the top genes overexpressed in Wilms' tumour.
aimTo evaluate the role of TopoIIalpha in Wilms' tumorigenesis and its prognostic value.
methodsTOP2A gene copy numbers were determined using the fluorescence in situ hybridisation technique, and protein expression levels of TopoIIalpha by immunostaining in 39 samples of primary and 18 samples of metastatic Wilms' tumour.
resultsTOP2A gene amplification was detected only in anaplastic Wilms' tumours, and none of the Wilms' tumours showed deletion of the TOP2A gene. TopoIIalpha protein overexpression was detected in 97% of Wilms' tumours, and correlated strongly with proliferation, as measured by Ki-67 (r = 0.85). The high TopoIIalpha expression was associated with the presence of vascular invasion, prominent apoptosis, metastases and adverse clinical outcomes (p<0.05).
conclusionsOur findings suggest that TopoIIalpha overexpression in Wilms' tumours is caused by a change at the transcription level, except for anaplastic Wilms' tumours, in which gene amplification was present. High levels of TopoIIalpha protein are correlated with tumour aggressiveness. The assessment of TopoIIalpha expression in Wilms' tumour may have prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.